Experience with abatacept in refractory lupus nephritis. (PubMed, Rheumatol Int) - Aug 31, 2023 - "The first case described a 49-year-old male with class IV lupus nephritis with nephrotic range proteinuria and high immunological activity refractory to conventional treatment with cyclophosphamide and corticosteroids and multitarget therapy with tacrolimus, mycophenolate mofetil and prednisone. Several biological therapies (rituximab, belimumab and tocilizumab) were unsuccessfully tried, so that abatacept was added to his background multitarget therapy showing complete clinical response...In successive renal flares with nephrotic proteinuria, she showed intolerance to rituximab and refractoriness to voclosporin...Based on our experience, abatacept should be considered as a safe rescue therapy in patients with refractory lupus nephritis and proteinuria with nephrotic range. In addition to this case, we reviewed the use of abatacept in lupus nephritis in the literature."
Clinical • Journal • Review • Chronic Kidney Disease • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Ana Ávila; Asunción Sancho Calabuig; Emma Calatayud; Juan José Alegre-Sancho; Marco Montomoli
|